Singapore Healthcare, Regulatory and Reimbursement Landscape – CountryFocus

GlobalData, the industry analysis specialist, has released its latest report: “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Singapore”. The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in Singapore. It identifies the key trends in the country’s healthcare market and provides insights into its demographic, regulatory, and reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData’s team of industry experts.

Singapore’s pharmaceutical market value in terms of US dollars was worth $0.7B in 2012, which increased at a CAGR of 7.4% to $1.0B in 2017. The increasing pharmaceutical market value is attributed to high life expectancy, expansion of healthcare system, developed medical infrastructure, improved patient access, and an increasing number of foreign pharmaceutical companies with a regional headquarters. Singapore’s medical devices market was valued at $2.55B in 2016, and was estimated to be $2.50B in 2019. The rapidly aging population drives demand for innovative medical technologies and therapeutic devices.

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in Singapore, and includes:

• An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers

• Profiles and SWOT analyses of the major players in the pharmaceutical market: Roche, Novartis, Merck, GlaxoSmithKline, and Haw Par

• Profiles and SWOT analyses of the major players in the medical device market: Medtronic, Becton Dickinson, Baxter International, Zimmer Biomet, and Edwards Lifesciences

• An insightful review of the COVID-19 epidemiology, COVID-19 impact and developments in healthcare market, HealthTech landscape, reimbursement and regulatory landscape, with analysis covering details of the country’s healthcare reimbursement process, regulatory agencies and the approval processes for new drugs and medical devices

• Detailed analysis of the country’s healthcare policy highlights, demographics, healthcare infrastructure and healthcare expenditure

• An overview of the opportunities for and challenges to growth in the Singaporean healthcare market

Reasons to buy

This report will enhance your decision-making capability by allowing you to:

• Develop business strategies by understanding the trends shaping and driving Singapore’s healthcare market

• Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments and companies likely to impact Singapore’s healthcare market in the future

• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing competitors’ performance

• Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment and strategic partnership

Table of Contents

1 Table of Contents

1.1 List of Figures

1.2 List of Tables

2 Executive Summary

2.1 Executive Summary – Overview

2.2 Key Highlights

2.3 Key Highlights: Healthcare Start-Ups in Singapore

2.4 Key Events: Singapore Healthcare History, 2002–2020

2.5 Key Events: Singapore Pharmaceutical Market

2.6 Key Events: M&As, VC & PE Deals, Global Pharmaceutical Market, 2019–2020

2.7 Key Events: Mergers and Acquisitions

2.8 Country Profile, Singapore, 2019

3 Overview of Pharmaceutical Market

3.1 Pharmaceutical Market – Overview

3.2 Pharmaceutical Market – Exports

3.3 Pharmaceutical Market – Imports

3.4 Pharmaceutical Market – Supply Channels, Singapore

3.5 Pharmaceutical Market – Market Segments

3.6 COVID-19 Epidemiology, Singapore

3.7 COVID-19 Impact and Developments in Healthcare Market, Singapore

3.8 Pharmaceutical Market – Major Players

4 Overview of Medical Devices Market

4.1 Medical Device Market – Overview

4.2 Medical Device Market – Major Segments

4.3 Medical Device Market – Major Players

5 Pharmaceutical and Medical Device Market – Drivers and Barriers

5.1 Drivers

5.2 Barriers

6 Deal analysis

6.1 Deal Analysis: M&A, VC, and PE Deals, Pharmaceutical Market, Singapore 2019–2020

7 HealthTech Landscape

7.1 HealthTech Landscape

7.1.1 HealthTech Deals Landscape, Singapore

7.2 Key HealthTech Deals, Singapore

7.3 Adoption of Technology in Healthcare, Singapore

7.4 Key Developments: Technology in Healthcare, Singapore

7.5 Regulatory Scenario Covering Use of Technology in Healthcare

7.6 HealthTech Landscape- Singapore- Benefits and Risks

8 Market Access

8.1 Overview of Healthcare System, Singapore

8.2 Reimbursement of Medicinal Products, Singapore

8.3 Overview of Public and Private Insurance Providers, Singapore

8.4 Healthcare Spending and Health Price Index, Singapore

8.5 Pricing Policies, Singapore

8.3 Regulatory Landscape, Singapore

8.3.1 Market Authorization for Pharmaceutical Drugs, Singapore

8.3.2 Market Authorization for Medical Devices, Singapore

8.3.3 Intellectual Property Rights, Patent, Singapore

8.3.4 Intellectual Property Rights, Trademark, Singapore

8.3.5 Pharmaceutical Clinical Trials Landscape, Singapore

8.3.6 Clinical Trial Regulations, Singapore

8.3.7 Exports and Imports Regulation, Singapore

8.3.8 Pharmacy Regulation, Singapore

8.3.9 Pharmaceutical Advertising Regulations, Singapore

8.3.10 Labeling and Packaging Regulations, Singapore

9 Country Healthcare Landscape

9.1 Singapore Healthcare Policy Highlights

9.2 Healthcare Facilities, Singapore

9.3 Healthcare Parameters, Singapore

9.4 Life Expectancy and Immunization Rate, Singapore

9.5 Environmental Health, Singapore

9.6 Healthcare Personnel, Singapore

9.7 Disease Burden, Singapore

9.8 Healthcare Expenditure

10 Trade Associations, Singapore

11 Trade Fairs, Singapore

12 Opportunities and Challenges

13 Appendix

13.1 Research Methodology

13.1.1 Coverage

13.1.2 Secondary Research

13.1.3 Forecasts

13.1.4 Expert Panel

13.2 Bibliography

13.3 Contact Us

13.4 Disclaimer

List of Tables

Table 1: Major Therapeutic Areas, Singapore, 2020

Table 2: COVID-19 Indicators (Number of cases), Global and Singapore, 2020

Table 3: COVID-19 Clinical Trials, Singapore, 2020

Table 4: COVID-19 Test Kits available for Diagnosis of COVID-19 , Singapore, 2020

Table 5: COVID-19 Test Kits available for Sample Collection, Singapore, 2020

Table 6: COVID-19 Test Kits available for Gene Sequencing, Singapore, 2020

Table 7: Medical Devices Market, Singapore, Revenue by Segment, 2018

Table 8: Government Healthcare Cost Subsidies, Singapore, 2020

Table 9: MediSave Allocation Rate, Singapore, 2020

Table 10: Drug Dossier Format, Singapore, 2020

Table 11: Fees for New Drug Application, Singapore, 2020

Table 12: Fees for Generic Drug Application, Singapore, 2020

Table 13: Fees for Biosimilar Application, Singapore, 2020

Table 14: General Risk Classification System, Singapore, 2020

Table 15: IVD Medical Devices Classification System, Singapore, 2020

Table 16: Fees For Medical Devices Registration, Singapore, 2020

Table 17: Patent Registration Fees, Singapore, 2020

Table 18: Trademark Registration Fees, Singapore, 2020

Table 19: Importer License Fees, Singapore

Table 20: Pharmacy License Fees, Singapore

Table 21: Label of a Pharmaceutical Unit Carton, Singapore

Table 22: Label of a Pharmaceutical Inner Label, Singapore

Table 23: Label of a Pharmaceutical Blister/Strips, Singapore

List of Figures

Figure 1: Pharmaceutical Market, Singapore, Revenue ($B), 2012–2019

Figure 2: Medical Devices Market, Singapore, Revenue ($B), 2016–2019

Figure 3: Healthcare Startups in Singapore, Singapore, 2020

Figure 4: Number of Deals (2019–2020)

Figure 5: 2019–2020 Deal Overview by Region

Figure 6: Country Profile, Singapore, 2019

Figure 7: Pharmaceutical Market, Singapore, Revenue ($B), 2012–2019

Figure 8: Pharmaceutical Market, Singapore, Revenue Forecast ($B), 2020–2024

Figure 9: Pharmaceutical Market, Singapore, Pharmaceutical Exports ($B), 2012–2019

Figure 10: Pharmaceutical Market, Singapore, Top Export Partners, 2019

Figure 11: Pharmaceutical Market, Singapore, Pharmaceutical Imports, ($B), 2012–2019

Figure 12: Pharmaceutical Market, Singapore, Top Import Partners, 2019

Figure 13: Pharmaceutical Market, Supply Chain, Singapore, 2020

Figure 14: Growth of Biopharmaceutical Sector, Singapore, 2020

Figure 15: List of Registered Biosimilars, Singapore, 2009–2019

Figure 16: OTC Market, Singapore, Revenue ($B), 2012–2018

Figure 17: OTC Market by Drug Category, Singapore, Revenue ($M), 2018

Figure 18: Major Therapeutic Areas, Singapore, 2020

Figure 19: COVID-19 (Number of cases), Singapore, 2020

Figure 20: COVID-19 (Number of deaths), Singapore, 2020

Figure 21: Medical Devices Market, Singapore, Revenue ($B), 2016–2019

Figure 22: Medical Devices Market, Singapore, Revenue by Segment ($M), 2018

Figure 23: Medical Devices Market, Singapore, Revenue ($B) of Major Companies, 2019

Figure 24: Deal Value and Deal Count, Pharmaceutical Market, Singapore, 2019–2020

Figure 25: Deal Value and Deal Count Quarterly, Pharmaceutical Market, Singapore, 2019

Figure 26: Deal Value and Deal Count Sub-types, Pharmaceutical Market, Singapore, 2019–2020

Figure 27: Pharmaceutical Market, Singapore, Top Five Therapy Areas by Deal Value ($M), 2019–2020

Figure 28: Pharmaceutical Market, Singapore, Venture Capital Financing Deals by Therapy Area, 2019–2020

Figure 29: Pharmaceutical Market, Singapore, Top Five Therapy Areas by Deal Number, 2019–2020

Figure 30: Medical Devices Market, Singapore, M&A Deals by Therapy Area, 2019–2020

Figure 31: Deal Value, HealthTech, Singapore, 2019–2020

Figure 32: Deal Count, HealthTech, Singapore, 2019–2020

Figure 33: Overview of Healthcare System, Singapore, 2020

Figure 34: MOH Organizational Structure, Singapore, 2020

Figure 35: Standard Drug List Formation, Singapore

Figure 36: Overview of Expedited Evaluation Process, Singapore, 2020

Figure 37: Overview of Full Evaluation Process, Singapore, 2020

Figure 38: Healthcare Financing, Singapore, 2020

Figure 39: Integrated Shield Plans (IPs), Singapore, 2020

Figure 40: OOP Expenditure (% of total expenditure on health), Singapore, 2012–2016

Figure 41: Annual Rate of Change (%), Health Price Index, Singapore, 2012–2019

Figure 42: HSA Organizational Structure, Singapore, 2020

Figure 43: Drug Registration Process, Singapore, 2020

Figure 44: Medical Devices Registration, Singapore, 2020

Figure 45: Patent Approval Process, Singapore, 2020

Figure 46: Trademark Approval Process, Singapore, 2020

Figure 47: Pharmaceutical Clinical Trials Count by Trial Status, Singapore, 2019–2020

Figure 48: Pharmaceutical Clinical Trials Count by Phase, Singapore, 2019–2020

Figure 49: Pharmaceutical Clinical Trials Count by Indication, Singapore, 2019–2020

Figure 50: Top Five Pharmaceutical Clinical Trials Sponsors by Count, Singapore, 2019–2020

Figure 51: CTA-CTN Regulatory Roadmap, Singapore, 2020

Figure 52: CTC Regulatory Roadmap, Singapore, 2020

Figure 53: Hospitals by Type (number), Singapore, 2012–2018

Figure 54: Hospitals (number), Singapore, 2012–2018

Figure 55: Acute Hospital Beds (number), Singapore, 2012–2018

Figure 56: Psychiatric Hospital Beds (number), Singapore, 2012–2018

Figure 57: Community Hospital Beds (number), Singapore, 2012–2018

Figure 58: Life Expectancy at Birth, Singapore, 2012–2018

Figure 59: Immunization Rate (%), Singapore, 2012–2018

Figure 60: PM2.5 (µg per m3), Singapore, 2012–2018

Figure 61: CO Emission (µg per m3) at Maximum 8-Hour Mean, Singapore, 2012–2018

Figure 62: Number of Physicians, Singapore, 2012–2018

Figure 63: Number of Dentists, Singapore, 2012–2018

Figure 64: Number of Pharmacists, Singapore, 2012–2018

Figure 65: Number of Nurses, Singapore, 2012–2018

Figure 66: Major Causes of Mortality (number of deaths), Singapore, 2016

Figure 67: Major Causes of Male Mortality (number of deaths), Singapore, 2016

Figure 68: Major Causes of Female Mortality (number of deaths), Singapore, 2016

Figure 69: Disability-Adjusted Life Years by Major Disease (thousands), Singapore, 2016

Figure 70: Healthcare Expenditure as Percentage of Gross Domestic Product (%), Singapore, 2012–2016

Figure 71: Public–Private Share (%), Singapore, 2012–2016

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports